Key result
Non-statin therapies drive progressively lower LDL-C targets in secondary prevention guidelines.
Why the study?
Clinical guidelines for lipid control in secondary prevention have evolved with new lipid-lowering drugs beyond statins, necessitating updated evidence synthesis.
Answers are grounded in this paper and cite their sources.
Clinical practice guidelines have gradually reduced LDL-C limits for patients with established cardiovascular disease due to the advent of non-statin drugs that allow major reductions in LDL-C levels.
The control of plasma lipids, and especially LDL-C levels is one of the actions on which clinical guidelines for reducing the risk of suffering a cardiovascular event are based, especially in secondary prevention. Cardiovascular prevention starts with lifestyles: a healthy diet, weight control and physical exercise. Statins are the first line drug due to the large body of evidence demonstrating their safety and efficacy. With the advent of drugs that allow major reductions in LDL-C levels, clinical practice guidelines have gradually reduced their limits for this substance, especially in patients with established cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Javier Garjón (2025) conducted a review in atherosclerotic cardiovascular disease. lipid-lowering drugs was evaluated. Clinical practice guidelines have gradually reduced LDL-C limits for patients with established cardiovascular disease due to the advent of non-statin lipid-lowering drugs.
Synapse has enriched 9 related papers. Consider them for comparative context: